Recent Updates
Recently added Catalysts
JAZZ Positive Sentiment Score: 75/100

Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan...

Key Takeaway: Jazz Pharmaceuticals has announced that it will webcast its corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference. The presentation, scheduled for January 9, 2023, will be led by CEO Bruce Cozadd and will include an overview of the company's business and financial updates. Following the live presentation, a replay of the webcast will be available on the company's website for 30 days. This event highlights Jazz Pharmaceuticals' commitment to engaging with investors and sharing important business information.

Market Sentiment Analysis

POSITIVE FACTORS

  • Jazz Pharmaceuticals is set to present at a prestigious conference.
  • The company aims to provide insights into its business and financials.
  • The webcast allows wider access for investors and stakeholders.

Full Press Release Details

DUBLIN , Jan. 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will webcast its corporate presentation at the 41 st Annual J.P. Morgan Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 9, 2023 , at 3:45 p.m. PST / 11:45 p.m. GMT .
A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . A replay of the webcast will be available on the website for 30 days following the conference.
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com for more information.
Investors: Andrea N. Flynn , Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland , +353 1 634 3211 U.S., +1 650 496 2717
Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc [email protected] Ireland , +353 1 637 2141 U.S., +1 215 867 4948
SOURCE Jazz Pharmaceuticals plc

21 %

Frequently Asked Questions

When is the J.P. Morgan Healthcare Conference presentation?

The presentation is on January 9, 2023, at 3:45 p.m. PST.

How can I access the live webcast of the presentation?

You can access the live webcast via the Investors section of the Jazz Pharmaceuticals website.

Will the presentation be available after the conference?

Yes, a replay will be available for 30 days following the conference.

What areas does Jazz Pharmaceuticals focus on?

Jazz Pharmaceuticals focuses on neuroscience and oncology.

Where is Jazz Pharmaceuticals headquartered?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Last updated: Jan 3, 2023